Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theophylline and N-acetylcysteine for Preventing Contrast-Induced Nephropathy
NCT02088502Phase 3Unknown
- Start
- Sep 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in contrast-induced nephropathy (CIN) comparing N-acetylcysteine, Theophylline and Theophylline plus N-acetylcysteine (3 arms). Primary endpoint: Plasma creatinine level at 48 hours. Status: unknown.
02
Drugs
theophyllineacetylcysteine
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT02088502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088502.